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Tingting Huang, Zhe Zhang and Xiaoying Zhou
Abstract
Nasopharyngeal carcinoma (NPC) is a malignancy with unique biological and 
clinical characteristics. It has highly associated with Epstein–Barr virus (EBV) 
infection and is sensitive to radiotherapy. Due to the extreme relevance between 
EBV infection and incidence of NPC, testing antibodies against EBV has been 
applied to screening “high-risk” populations of NPC. The pathological diagnosis of 
nasopharyngeal biopsy is the gold standard for the diagnosis of NPC. Radiotherapy 
has been recognized as the first choice for NPC treatment. With the improvement 
of intensity-modulated radiation therapy (IMRT), the 5-year disease-specific sur-
vival rate in NPC patients at an early stage has reached 95%. However, the efficacy 
brought by radiotherapy has reached the bottleneck in advanced patients. Recently, 
the 5-year overall survival rate was increased around 60-80% in locoregionally 
advanced NPC patients by introducing concurrent chemoradiotherapy. In addition, 
molecular targeted therapy and immunotherapy have been introduced to many 
clinical trials. In this chapter, we mainly focus on the current early screening and 
diagnosis of NPC patients, and the development of therapeutic approaches.
Keywords: nasopharyngeal carcinoma, population-based screening, symptoms, 
diagnosis, treatment
1. Introduction
As a part of the pharynx, the nasopharynx lies behind and communicates with 
the nasal cavities. It is up to the cranial base, down to the soft palate plane, forward 
through the back of the nose to the nasal cavity, and pharynx tonsils in the back-
ward. Behind the inferior turbinate, there is an opening of the eustachian tube, 
which leads through the nasopharynx to the tympanic cavity. A recess in the lateral 
of the pharyngeal wall extending posteriorly to the opening of the eustachian tubal 
torus, which is called Fossa of Rosenmüller, is the predilection site of nasopharyn-
geal carcinoma (NPC).
As one of the malignant head and neck cancer, NPC arises from epithelial cells 
within the nasopharyngeal mucosa, with a unique geographical and ethnic dis-
tribution.. Epstein–Barr virus (EBV) infection, carcinogen exposure, and genetic 
susceptibility contribute to the carcinogenesis of NPC. In the endemic area, more 
than 95% of NPC patients were EBV positive, therefore, testing antibodies against 
EBV or cell-free EBV DNA has been established for screening assays targeted 
“high-risk” populations of NPC. Nasopharyngeal endoscopy is recommended for 
EBV-seropositive individuals to find out NPC patients at an early stage. The com-
mon clinical symptoms of NPC were nasal congestion, bloody nose, hearing loss, 
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and headache, but not specific at early stages. At present, the pathological diagnosis 
of nasopharyngeal biopsy remains the golden standard for NPC. Most undifferenti-
ated NPC is moderately sensitive to radiation therapy, leading it the first choice 
for NPC treatment. Taking advantage of accurate staging systems, modern radio-
therapy techniques, and concurrent chemotherapy, the locoregional control and 
overall survival of NPC patients have substantially improved along with the decline 
of treatment-induced toxicity in the past two decades. However, residual/recurrent 
disease and metastatic disease are still crucial challenges in managing NPC.
1.1 Epidemiology
Globally, NPC is uncommon cancer with approximately 129,000 new cases 
reported in 2018 and accounting for 0.7% of all cancers [1]. The incidence of NPC is 
relatively concentrated, about 80% of NPC occurs in Asia, and China accounts for 
almost half of the total [2]. For instance, the incidence rate in North America and 
Europe is less than 1/100,000 person-years, but greater than 20/100,000 person-
years in Southern China and Southeast Asia [3, 4]. Importantly, NPC incidence is 
higher in males than in females, with a ratio of 2-3 [5]. The age-specific incidence of 
NPC is different from other types of cancer as well. The bimodal distribution of age 
showed two peaks between 16 and 20 and 45-60 years [3]. Besides, family aggregation 
is a characteristic of NPC in the endemic area which is well documented [6, 7]. Even 
people migrate from Southern China to non-endemic areas, the incidence remains 
high, suggesting that genetic inheritance is one of the main factors for NPC patho-
genesis. However, the reduced incidence has been observed in second-generation 
migrants [8]. In addition, according to recent epidemiology studies, the global inci-
dence of NPC is also declining gradually [9–11]. These findings indicate that lifestyle 
alterations are highly correlated with the pathogenesis of NPC.
1.2 Etiology
So far, the etiology of NPC is not fully clear. It is widely accepted that genetic 
susceptibility, EBV infection, and exposure to harmful carcinogens such as intake 
of salted fish and preserved food, etc., are the main pathogenic factors for NPC. 
The single factor mentioned above can not induce the occurrence of NPC in animal 
models, therefore all these factors contribute together and their interaction might 
be more important and worth deeply understanding [12]. Recently, poor oral 
hygiene has been proposed as a risk factor for NPC [13]. The composition of the oral 
microbiome is shown to be different between NPC patients and their population-
based controls [14]. Moreover, the anaerobic metabolites of F. nucleatum, n-butyrate 
acid is a strong lytic-cycle inducer of EBV [15]. More potential pathogenic factors 
are being discovered.
In the endemic area, almost all NPC patients are associated with EBV infection 
and are more sensitive to radiotherapy [16]. Besides, it is difficult to achieve effec-
tive treatment by surgery in NPC patients, because the anatomy of the nasopharynx 
is concealed and the peripheral nerves and blood vessels, and more than 80% of 
patients show lymph node metastasis at the time of diagnosis [17, 18]. Therefore, 
radiotherapy is the first choice in the treatment of NPC. At present, the local control 
rate of NPC patients under radiotherapy exceeds 90%, and the 5-year survival rate 
is close to 80% [19, 20]. It is noteworthy that early diagnosis is a key point. The 
earlier diagnosis of NPC patients, the greater improvement of survival [21]. To date, 
distant organ metastasis remains the largest obstacle and the main factor of failure. 
In this chapter, we mainly introduce the early population screening of NPC in the 






4.3 Disease surveillance, management of residual/recurrent disease
Close follow-up for NPC patients is essential in terms of disease surveillance. 
Despite relatively desirable treatment outcomes among solid cancers, unfortu-
nately, about 10-20% of NPC patients will suffer from residual disease or develop 
recurrent disease after primary treatment, T4 disease among them is reported with 
up to 45% local recurrence rate [43, 63–67]. Early detection is critical given that 
extent of relapse determines the chance of salvage, and patients with T1-T2 recur-
rent disease are more likely to achieve long-term benefit [68, 69]. Initial assessment 
of residual disease is usually conducted at 12 weeks after the completion of RT or 
CRT [70, 71]. A detailed history and physical examination, nasopharyngoscopy 
(with/without biopsy), and radiation imaging (CT/MRI/18F-FDG-PET-CT) are 
highly recommended in a comprehensive response assessment. Recently, the post-
treatment plasma EBV DNA is considered for monitoring for NPC in the context of 
locoregional failure, distant metastasis, and survival [72].
Emerging evidence suggests that aggressive salvage modalities might increase 
the chances of better prognosis among patients with recurrent NPC [68, 73, 74]. 
Neck dissection is widely recommended for isolated regional failure. Re-irradiation 
is considered for a tumor that recurs more than one year after the completion of 
primary RT. In contrast, salvage surgery is esteemed if the one recurs within one 
year and is resectable.
4.4 Management of metastatic disease
Patients with metastatic NPC have various clinical characteristics and out-
comes. Around 10% of newly diagnosed NPC patients present with synchronous 
distance metastases. Unfortunately, up to 15%-30% of the non-metastatic NPC 
patients will experience distant failure after primarily curative treatment [2, 48]. 
Compelling evidence suggests these patients may achieve a median overall survival 
of 10-15 months by receiving palliative chemotherapy. The overall survival can be 
improved among those who are indicated for locoregional RT and local treatment of 
metastatic lesions [63, 75–81]. Thus, a personalized treatment strategy is necessary 
for metastatic NPC. Researchers and clinicians have made a hard effort to build up 
predictive models for prognosis to stratify risk groups and provide treatment strate-
gies accurately [82–87].
Recommending by NCCN guideline, the first-line regimens of systemic therapy 
for NPC patients with recurrent, or unresectable, or metastatic disease are cispla-
tin plus gemcitabine. Other recommended regimens include the combination of 
cisplatin/5-fluorouracil, cisplatin or carboplatin/docetaxel or paclitaxel, carbopla-
tin/cetuximab, gemcitabine/carboplatin, as well as the single-use of them. A recent 
view suggests that neither VEGFR nor EGFR targeting therapies are recommended 
as high priority for recurrent and/or metastatic NPC, with unimpressive response 
rates around 10% or less [67, 88–93]. Reported toxicities of anti-VEGF therapy 
and anti-EGFR therapy can be severe and life-threatening, which should not be 
neglected.
Remarkably, several single-arm trials evaluating immunotherapy targeted the 
programmed death 1/programmed death-ligand 1 (PD1/PD-L1) pathway in recur-
rent/metastatic NPC patients have shown promising outcomes [94–96]. In prin-
ciple, NPC tumors are featured by high PD-L1 expression and abundant infiltration 
of non-malignant lymphocytes, suggesting the feasibility of immune checkpoint 
blockade therapies in NPC patients [97–100]. Some ongoing phase 3 trials investi-
gating anti-PD-1 therapies among treatment naïve locoregionally advanced disease, 
recurrent, or metastatic disease, will improve clinical practice [2]. Likewise, a phase 
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1 trial of a recombinant vaccinia virus (MVA-EL), which encodes an EBNA1/LMP2 
fusion protein designed to boost T-cell immunity to these antigens, has shown 
clinical efficacy in heavily pretreated NPCs [101]. Evidence from phage 2/3 RCTs on 
immunotherapies targeting EBV and/or PD1/PD-L1 is awaited to manage locore-
gional, recurrent, and metastatic NPC in the near future.
5. Conclusion
Early diagnosis and early therapy is the most effective method to improve the 
curative effect of NPC. It is necessary to strengthen the population-based screening 
of NPC in the endemic region and optimize the screening methods to elevate effi-
ciency. Improving the treatment approach is critical as well. With the great progress 
in staging systems, radiotherapy techniques, and concurrent chemotherapy, the 
locoregional control and overall survival of NPC patients have improved substan-
tially. Meanwhile, molecular targeted therapy and immunotherapy have gained 
much interest and are now being introduced to many clinical trials. Although 
encouraging outcomes are achieved, treatment-related toxicities, residual/recurrent 
disease, and metastatic disease are still crucial challenges in managing NPC, worthy 
of further attention and effort.
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